Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9421992 | PMC |
| http://dx.doi.org/10.1002/jha2.445 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Evaluation of FOXP3 Exons 2 and 7 Variants in Recurrent Pregnancy Loss among South Indian Women.
Curr Protein Pept Sci
September 2025
Department of Biotechnology & Bioinformatics, School of Life Sciences, University of Hyderabad, Prof. C.R. Rao Road, Hyderabad, India.
Introduction: One to two percent of women worldwide experience recurrent pregnancy loss (RPL), defined as the loss of two or more consecutive pregnancies before 20 weeks of gestation. Genetic factors, including variations in the FOXP3 gene, have been implicated in the unexplained etiology of RPL. This study aimed to identify and characterize novel genetic variants in exons 2 and 7 of the FOXP3 gene in South Indian women with idiopathic RPL and to analyze their potential impact on protein structure.
View Article and Find Full Text PDFClinical, biochemical, and genetic characterization of Lebanese patients with chronic granulomatous disease due to NCF2 pathogenic variants.
Clin Immunol
September 2025
Department of Experimental Pathology, Immunology, and Microbiology, Faculty of Medicine, American University of Beirut, Beirut, Lebanon; Division of Pediatric Infectious Diseases, Department of Pediatrics and Adolescent Medicine, American University of Beirut Medical Center, Beirut, Lebanon; Center
Chronic Granulomatous Disease (CGD) is caused by mutations in the NADPH oxidase complex that impair the ability of phagocytes to eliminate injested pathogens. As a result, patients with CGD suffer from recurrent infections and chronic inflammation. We report the clinical, biochemical, and genetic basis of the disease in 17 CGD patients from Lebanon.
View Article and Find Full Text PDFDual Targets, Two Paths: Amivantamab: A Promising Treatment for NSCLC With Exon 14 Skipping Mutations of MET.
J Thorac Oncol
September 2025
Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka-Sayama, Osaka, Japan. Electronic address:
HER2 gene mutations and matrix biomarkers in breast cancer.
Clin Biochem
September 2025
Department of Biochemistry, Azerbaijan Medical University, Baku, Azerbaijan. Electronic address:
Objective: Breast cancer (BC) remains a leading cause of morbidity and mortality among women globally. This study aims to investigate HER2 mutations in HER2-negative BC and evaluate the diagnostic potential of matrix metalloproteinases (MMP-7, MMP-9) and CYR61 as serum biomarkers.
Material And Methods: The study involved 74 women diagnosed with BC (HER2-positive: n = 33; HER2-negative: n = 33; triple negative: n = 8) and 25 healthy controls.
Impact of rare EGFR exon 19 insertion-deletion variants on tyrosine kinase inhibitor efficacy in non-small-cell lung cancer: a 5-year multicenter analysis.
ESMO Open
September 2025
Department of Pulmonary and Critical Care Medicine, Fuzong Clinical Medical College of Fujian Medical University & The 900th Hospital of Joint Logistic Support Force, PLA, Fuzhou, China. Electronic address:
Background: The clinical impact of rare epidermal growth factor receptor (EGFR) exon 19 insertion-deletion (19delins) variants on tyrosine kinase inhibitor (TKI) efficacy remains poorly characterized. We updated 5-year outcomes to evaluate long-term survival and optimal treatment strategies in advanced lung adenocarcinoma (LUAD) patients harboring these mutations.
Materials And Methods: In this multicenter prospective study, 36 treatment-naive advanced LUAD patients with EGFR 19delins mutations received first-generation (n = 26) or third-generation TKIs (n = 10).